By grouping the CDK2 and CDK4 expression levels of melanoma samples, survival analysis of patients in the high- and low-expression groups showed that the high expression of CDK2 and CDK4 significantly reduced the OS rate of patients with melanoma. The gene discussed is CDK4; the disease is melanoma.